On June 2, 2020, Dr. Kwatra and his collaborators published their findings on osimertinib’s efficacy against EGFRvIII+ glioblastoma in the …
Posts Categorized: Uncategorized
Press Release: Dr. Kwatra submits R01 grant to the NCI for his study entitled “Phase II trial of osimertinib in newly diagnosed GBM patients expressing EGFRvIII.”
Dr. Madan Kwatra, Director of Glioblastoma Drug Discovery Group, is pleased to announce his recent R01 grant submission to the …
Press Release: Musella Foundation Fellowships for Glioblastoma Drug Development
The Musella Foundation has again graciously funded fellowships for two Duke University students, Josh Engel and Caroline Maretz, to …
Press Release: Dr. Kwatra receives IND from the FDA to study osimertinib (AZD9291) in EGFRvIII-positive glioblastoma
Dr. Madan Kwatra, Director of the Glioblastoma Drug Discovery Group at Duke, is pleased to announce that the FDA …
Press Release: Amelia Garcia Fund Grant
The Amelia Garcia Fund at The Miami Foundation has presented The Glioblastoma Drug Discovery Lab at Duke University with a …
Press Release: Efficacy of Osimertinib (AZD9291) against EGFRvIII-positive Glioblastoma Presented at Society for Neuro-Oncology 2017 Annual Meeting
Dr. Madan Kwatra, Director of the Glioblastoma Drug Discovery Group at Duke, gave an oral presentation at the 2017 annual …
Press Release: Collaboration with Genzada to Develop Novel Therapies for Glioblastoma
Genzada Pharmaceuticals has awarded Dr. Kwatra, Director of Glioblastoma Drug Discovery Group at Duke, a two-year, $763,200 grant, titled “Evaluation …
Press Release: Collaboration with DelMar Pharmaceuticals
DelMar Pharmaceuticals has entered into a multi-year collaboration with Dr. Madan Kwatra, Director of the Glioblastoma Drug Discovery Group at …
Press Release: AstraZeneca Grants Award to Develop Osimertinib for EGFRvIII-Positive Glioblastoma
Dr. Madan Kwatra, Director of the Glioblastoma Drug Discovery Group at Duke, has been awarded a $97,109 grant for his …
Press Release: Project Details To Establish Preclinical Models For AYA Glioblastoma Patients
Project Details Objective Glioblastoma in adolescent and young adults (AYA), an age group spanning 15 to 39 years, is molecularly …